232 Comparative efficacy and safety of enoxaparin and fondaparinux in non-high risk acute pulmonary embolism: an adjusted propensity score analysis
| Autor: | Nicolas Meneveau, Vincent Descotes-Genon, Romain Chopard, Marie France Séronde, Paul Luporsi, Florent Briand, Alexandre Guignier, Yvette Bernard, Francois Schiele |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry Mortality rate Low molecular weight heparin macromolecular substances Heparin Fondaparinux medicine.disease Gastroenterology Surgery Pulmonary embolism Internal medicine Propensity score matching medicine Clinical endpoint Initial treatment Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Archives of Cardiovascular Diseases Supplements. 3:76 |
| ISSN: | 1878-6480 |
| DOI: | 10.1016/s1878-6480(11)70234-8 |
| Popis: | BackgroundGuidelines recommend low molecular weight heparin (LMWH) and fondaparinux (fonda) over unfractionated heparin (UFH) for initial treatment of acute pulmonary embolism (PE), except in patients (pts) at high risk of bleeding & with severe renal dysfunction. No trial has assessed the comparative efficacy of enoxaparin (enox) and fonda in this setting.MethodsProspective, multicenter registry. Pts with proven recent PE (symptom onset |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect